Waters Corporation Combines Strengths with Becton Dickinson
Waters Corporation (NYSE: WAT) has officially completed its merger with the Biosciences & Diagnostic Solutions segment of Becton, Dickinson and Company (NYSE: BDX). This strategic move positions Waters as a formidable global leader in life sciences and diagnostics, focusing on high-volume testing in regulated applications.
The company is excited to signify this major milestone in its journey by appointing Claire M. Fraser, Ph.D., to the Waters Board of Directors. This addition expands the board to 11 members, bringing valuable expertise as it steers the company towards new growth horizons.
Introducing Dr. Claire M. Fraser
Dr. Claire M. Fraser is a celebrated scientist in the field of genomics, boasting over 30 years of experience directing significant research initiatives. Most notably, she founded The Institute for Genome Sciences at the University of Maryland School of Medicine. Her robust academic background, including a B.S. in Biology and a Ph.D. in Pharmacology, positions her as a beacon of knowledge for Waters as it ventures into this new chapter.
Flemming Ørnskov, M.D., M.P.H., the Chairman of Waters, expressed his enthusiasm about the merger and Dr. Fraser’s appointment. He emphasized the importance of her extensive background in genomics and infectious diseases, which will be invaluable as Waters embarks on its next era of innovation and value generation.
Significance of the Merger
With this merger, Waters combines its technological expertise with BD's robust scientific capabilities. Udit Batra, Ph.D., President and CEO of Waters, highlighted the merger's significance, claiming that this union creates a powerhouse of scientific knowledge that spans various disciplines.
This merger not only enhances Waters' technological portfolio but also expands its market reach, ensuring they can meet unmet customer needs effectively while delivering sustained value to shareholders. The commitment to advancing global health remains central to the company’s mission.
Post-merger, Waters is now structured into four key divisions to streamline operations and focus more efficiently on testing in regulatory settings and adjacent markets:
New Divisions of Waters Corporation
- Waters Analytical Sciences: This division focuses on products and services connected to separations science and molecular characterization, enhancing capabilities in liquid chromatography and mass spectrometry.
- Waters Biosciences: Leveraging the strengths of BD Biosciences, this division emphasizes cellular analysis and flow cytometry technologies.
- Waters Advanced Diagnostics: Concentrating on diagnostic workflows, this division aims to provide essential services for various clinical settings.
- Waters Materials Sciences: This division focuses on diverse materials characterization techniques, serving industries like batteries and pharmaceuticals.
This development reflects Waters' commitment to navigating high-volume testing environments and fostering innovation across its divisions. The merger solidifies Waters' status as an industry leader, poised to enhance the development of large and small molecule therapeutics, food safety, and advanced diagnostics.
Transaction Details
The merger was executed through a Reverse Morris Trust transaction, where BD's businesses transitioned into a separate entity merging with a subsidiary of Waters. As a result, the former BD shareholders received approximately 0.135 shares of Waters common stock for each share they held, marking a favorable transition for all parties involved.
Looking Ahead
With this combination, Waters Corporation is set to revolutionize the life sciences landscape, and its shared culture of innovation remains a primary driver of its growth strategy. The company's talented team is eager to turn scientific challenges into innovations that significantly improve lives globally.
As Waters continues to deliver high-quality solutions and pioneering technologies, its journey is bound to enhance patient outcomes and ensure the safety of food and water across various sectors.
Frequently Asked Questions
What is the significance of the merger between Waters and BD?
The merger combines Waters' technological expertise with BD's strengths in diagnostics and biosciences, creating a leader in high-volume testing.
Who is Dr. Claire M. Fraser?
Dr. Fraser is a renowned genome scientist appointed to the Waters Board of Directors, bringing extensive expertise to guide the company’s growth.
What are the new divisions established by Waters?
Waters now operates four divisions: Analytical Sciences, Biosciences, Advanced Diagnostics, and Materials Sciences, each focusing on different areas of life sciences.
How will the merger impact shareholders?
The merger aims to deliver sustained value for shareholders by creating innovative solutions and addressing unmet customer needs globally.
What is the future outlook for Waters Corporation?
Waters is well-positioned for growth, leveraging its combined scientific capabilities to lead advancements in health, safety, and diagnostics.
